37 results on '"Sadighi Z"'
Search Results
2. Unusual magnetic resonance imaging presentation of post-BMT cerebral toxoplasmosis masquerading as meningoencephalitis and ventriculitis
- Author
-
Helton, K J, Maron, G, Mamcarz, E, Leventaki, V, Patay, Z, and Sadighi, Z
- Published
- 2016
- Full Text
- View/download PDF
3. Is immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations?
- Author
-
Kamiya-Matsuoka, C., primary, Metrus, N., additional, Weathers, S.-P., additional, Ross, J., additional, Shaw, K., additional, Penas-Prado, M., additional, Loghin, M., additional, Alfaro-Munoz, K., additional, O’Brien, B., additional, Harrison, R., additional, Sadighi, Z., additional, Majd, N., additional, Yung, W., additional, Meric-Bernstam, F., additional, Hambardzumyan, D., additional, and de Groot, J., additional
- Published
- 2019
- Full Text
- View/download PDF
4. 393O - Is immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations?
- Author
-
Kamiya-Matsuoka, C., Metrus, N., Weathers, S.-P., Ross, J., Shaw, K., Penas-Prado, M., Loghin, M., Alfaro-Munoz, K., O’Brien, B., Harrison, R., Sadighi, Z., Majd, N., Yung, W., Meric-Bernstam, F., Hambardzumyan, D., and de Groot, J.
- Published
- 2019
- Full Text
- View/download PDF
5. ED-27 * CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME IN MOVEMENT DISORDER IN CHILDHOOD THALAMIC TUMORS
- Author
-
Sadighi, Z., primary, Zabrowski, J., additional, Broniscer, A., additional, Gajjar, A., additional, and Khan, R., additional
- Published
- 2014
- Full Text
- View/download PDF
6. Effects of heat treatment on the characteristics of mechano-thermally synthesized nano-structured La0.8Ba0.2MnO3 powder
- Author
-
Sadighi, Z., primary, Ataie, A., additional, and Barati, M.R., additional
- Published
- 2013
- Full Text
- View/download PDF
7. PEDIATRICS CLINICAL RESEARCH
- Author
-
Antony, R., primary, Zagardo, M., additional, Gujrati, M., additional, Lin, J., additional, Antony, R., additional, Al-Rahawan, M., additional, Broniscer, A., additional, Bhardwaj, R., additional, Hampton, C., additional, Ozols, V., additional, Chakravadhanula, M., additional, Bouffet, E., additional, Hawkins, C., additional, Scheinemann, K., additional, Zelcer, S., additional, Johnston, D., additional, Lafay-Cousin, L., additional, Larouche, V., additional, Jabado, N., additional, Carret, A. S., additional, Hukin, J., additional, Eisenstat, D., additional, Pond, G., additional, Poskitt, K., additional, Wilson, B., additional, Bartels, U., additional, Tabori, U., additional, Dhall, G., additional, Haley, K., additional, Finlay, J., additional, Rushing, T., additional, Sposto, R., additional, Seeger, R., additional, Garvin, J., additional, Rupani, K., additional, Stark, E., additional, Anderson, R., additional, Feldstein, N., additional, Grill, J., additional, Hargrave, D., additional, Massimino, M., additional, Jaspan, T., additional, Varlet, P., additional, Jones, C., additional, Morgan, P., additional, Le Deley, M. C., additional, Azizi, A., additional, Canete, A., additional, Saran, F., additional, Bachir, J., additional, Bubuteishvili-Pacaud, L., additional, Rousseau, R., additional, Vassal, G., additional, Gupta, S., additional, Robinson, N., additional, Dhir, N., additional, Wong, K., additional, Zhou, S., additional, Kumabe, T., additional, Kawaguchi, T., additional, Saito, R., additional, Kanamori, M., additional, Yamashita, Y., additional, Sonoda, Y., additional, Tominaga, T., additional, Miyagawa, T., additional, Nwachukwu, C., additional, Youland, R., additional, Laack, N., additional, Filipek, I., additional, Drogosiewicz, M., additional, Polnik, M. P.-, additional, Swieszkowska, E., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Perek, D., additional, Grajkowska, W., additional, Roszkowski, M., additional, Sobol, G., additional, Musiol, K., additional, Wachowiak, J., additional, Kazmierczak, B., additional, Pogorzelski, J. P. -, additional, Mlynarski, W., additional, Szewczyk, B. Z.-, additional, Wysocki, M., additional, Niedzielska, E., additional, Kowalczyk, J., additional, Slusarz, H. W. -, additional, Balwierz, W., additional, Czepko, E. Z. -, additional, Szolkiewicz, A., additional, Perek-Polnik, M., additional, Lastowska, M., additional, Chojnacka, M., additional, Tarasinska, M., additional, Perreault, S., additional, Chao, K., additional, Ramaswamy, V., additional, Shih, D., additional, Remke, M., additional, Luu, B., additional, Schubert, S., additional, Fisher, P., additional, Partap, S., additional, Vogel, H., additional, Taylor, M., additional, Goumnerova, L., additional, Cho, Y.-J., additional, Robison, N., additional, Brown, R., additional, Cloughesy, T., additional, Davidson, T. B., additional, Krieger, M., additional, Berger, M., additional, Perry, A., additional, Gilles, F., additional, Finlay, J. L., additional, Khemani, J., additional, Britt, B., additional, Grimm, J., additional, Ruge, M. I., additional, Blau, T., additional, Hafkemeyer, V., additional, Hamisch, C., additional, Klinger, K., additional, Simon, T., additional, Sadighi, Z., additional, Ellezam, B., additional, Guindani, M., additional, Ater, J., additional, Shimizu, Y., additional, Arai, H., additional, Miyajima, M., additional, Shimoji, K., additional, Kondo, A., additional, Shinohara, E., additional, Perkins, S., additional, DeWees, T., additional, Slavc, I., additional, Chocholous, M., additional, Leiss, U., additional, Haberler, C., additional, Peyrl, A., additional, Azizi, A. A., additional, Dieckmann, K., additional, Woehrer, A., additional, Dorfer, C., additional, Czech, T., additional, Spence, T., additional, Picard, D., additional, Barszczyk, M., additional, Kim, S.-K., additional, Ra, Y.-S., additional, Fangusaro, J., additional, Toledano, H., additional, Nakamura, H., additional, Fan, X., additional, Muraszko, K. M., additional, Ng, H.-K., additional, Halliday, W., additional, Shago, M., additional, Hawkins, C. E., additional, Huang, A., additional, Suzuki, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Hulleman, E., additional, Idema, S., additional, Noske, D., additional, Wolf, N., additional, Hendrikse, H., additional, Vandertop, P., additional, Kaspers, G. J., additional, Muller, K., additional, Schlamann, A., additional, Warmuth-Metz, M., additional, Pietsch, T., additional, Pietschmann, S., additional, Kortmann, R.-D., additional, Kramm, C. M., additional, von Bueren, A. O., additional, Walston, S., additional, Williams, T., additional, Hamstra, D., additional, Oh, K., additional, Pelloski, C., additional, Zhukova, N., additional, Pole, J., additional, Mistry, M., additional, Fried, I., additional, Lapperiere, N., additional, Dirks, P., additional, An, J., additional, Alon, N., additional, Nathan, P., additional, Greenberg, M., additional, and Malkin, D., additional
- Published
- 2013
- Full Text
- View/download PDF
8. CLIN-PATHOLOGY
- Author
-
Alexandru, D., primary, Satyadev, R., additional, So, W., additional, Lee, S. H., additional, Lee, Y. S., additional, Hong, Y.-K., additional, Kang, C. S., additional, Rodgers, S. D., additional, Marascalchi, B. J., additional, Strom, R. G., additional, Riina, H., additional, Samadani, U., additional, Frempong-Boadu, A., additional, Babu, R., additional, Sen, C., additional, Zagzag, D., additional, Anderson, M. D., additional, Abel, T. W., additional, Moots, P. L., additional, Odia, Y., additional, Orr, B. A., additional, Eberhart, C. G., additional, Rodriguez, F., additional, Sweis, R. T., additional, Lavingia, J., additional, Connelly, J., additional, Cochran, E., additional, van den Bent, M., additional, Hartmann, C., additional, Preusser, M., additional, Strobel, T., additional, Dubbink, H. J., additional, Kros, J. M., additional, von Deimling, A., additional, Boisselier, B., additional, Sanson, M., additional, Halling, K. C., additional, Diefes, K. L., additional, Aldape, K., additional, Giannini, C., additional, Rodriguez, F. J., additional, Ligon, A. H., additional, Horkayne-Szakaly, I., additional, Rushing, E. J., additional, Ligon, K. L., additional, Vena, N., additional, Garcia, D. I., additional, Douglas Cameron, J., additional, Raghunathan, A., additional, Wani, K., additional, Armstrong, T. S., additional, Vera-Bolanos, E., additional, Fouladi, M., additional, Gajjar, A., additional, Goldman, S., additional, Lehman, N. L., additional, Metellus, P., additional, Mikkelsen, T., additional, Necesito-Reyes, M. J. T., additional, Omuro, A., additional, Packer, R. J., additional, Partap, S., additional, Pollack, I. F., additional, Prados, M. D., additional, Ian Robbins, H., additional, Soffietti, R., additional, Wu, J., additional, Gilbert, M. R., additional, Aldape, K. D., additional, Prosniak, M., additional, Harshyne, L. A., additional, Andrews, D. W., additional, Craig Hooper, D., additional, Kagawa, N., additional, Hosen, N., additional, Kijima, N., additional, Hirayama, R., additional, Chiba, Y., additional, Yamamoto, F., additional, Kinoshita, M., additional, Hashimoto, N., additional, Fujimoto, Y., additional, Yoshimine, T., additional, Hu, J., additional, Nuno, M., additional, Patil, C., additional, Rudnick, J., additional, Phuphanich, S., additional, Bannykh, S., additional, Chu, R., additional, Yu, J., additional, Black, K., additional, Choi, J., additional, Kim, D., additional, Shim, K. W., additional, Kim, S. H., additional, Kanno, H., additional, Nishihara, H., additional, Tanaka, S., additional, Yanagi, T., additional, Buczkowicz, P., additional, Khuong-Quang, D.-A., additional, Rakopoulos, P., additional, Bouffet, E., additional, Morrison, A., additional, Bartels, U., additional, Pfister, S. M., additional, Jabado, N., additional, Hawkins, C., additional, Weinberg, B. D., additional, Newell, K. L., additional, Kumar, P., additional, Wang, F., additional, Venneti, S., additional, Madden, M., additional, Coyne, T., additional, Phillips, J., additional, Gorovets, D., additional, Huse, J., additional, Kofler, J., additional, Lu, C., additional, Tihan, T., additional, Sullivan, L., additional, Santi, M., additional, Judkins, A., additional, Thompson, C., additional, Perry, A., additional, Iorgulescu, J. B., additional, Laufer, I., additional, Hameed, M., additional, Lis, E., additional, Boland, P., additional, Komotar, R., additional, Bilsky, M., additional, Amato-Watkins, A. C., additional, Neal, J., additional, Rees, A. D., additional, Davies, J. S., additional, Hayhurst, C., additional, Lu-Emerson, C., additional, Snuderl, M., additional, Davidson, C., additional, Kirkpatrick, N. D., additional, Huang, Y., additional, Duda, D. G., additional, Ancukiewicz, M., additional, Stemmer-Rachamimov, A., additional, Batchelor, T. T., additional, Jain, R. K., additional, Ellezam, B., additional, Theeler, B. J., additional, Sadighi, Z. S., additional, Mehta, V., additional, Tran, M.-D. T., additional, Adesina, A. M., additional, Puduvalli, V. K., additional, and Bruner, J. M., additional
- Published
- 2012
- Full Text
- View/download PDF
9. CLIN-PEDIATRICS CLINICAL RESEARCH
- Author
-
Packer, R. J., primary, Rood, B. R., additional, Onar-Thomas, A., additional, Goldman, S., additional, Fisher, M. J., additional, Smith, C., additional, Boyett, J., additional, Kun, L., additional, Nelson, M. B., additional, Compton, P., additional, Macey, P., additional, Patel, S., additional, Jacob, E., additional, O'Neil, S., additional, Finlay, J., additional, Harper, R., additional, Legault, G., additional, Chhabra, A., additional, Allen, J. C., additional, Si, S. J., additional, Flores, N., additional, Haley, K., additional, Malvar, J., additional, Fangusaro, J., additional, Dhall, G., additional, Sposto, R., additional, Davidson, T. B., additional, Finlay, J. L., additional, Krieger, M., additional, Zhou, T., additional, Miller, D. C., additional, Geyer, J. R., additional, Pollack, I. F., additional, Gajjar, A., additional, Cohen, B. H., additional, Nellan, A., additional, Murray, J. C., additional, Honeycutt, J., additional, Gomez, A., additional, Head, H., additional, Braly, E., additional, Puccetti, D. M., additional, Patel, N., additional, Kennedy, T., additional, Bradley, K., additional, Howard, S., additional, Salamat, S., additional, Iskandar, B., additional, Slavc, I., additional, Peyrl, A., additional, Chocholous, M., additional, Kieran, M., additional, Azizi, A., additional, Czech, T., additional, Dieckmann, K., additional, Haberler, C., additional, Sadighi, Z. S., additional, Ellezam, B., additional, Khatua, S., additional, Ater, J., additional, Biswas, A., additional, Kakkar, A., additional, Goyal, S., additional, Mallick, S., additional, Sarkar, C., additional, Sharma, M. C., additional, Julka, P. K., additional, Rath, G. K., additional, Glass, T., additional, Cochrane, D. D., additional, Rassekh, S. R., additional, Goddard, K., additional, Hukin, J., additional, Deopujari, C. E., additional, Khakoo, Y., additional, Hanmantgad, S., additional, Forester, K., additional, McDonald, S. A., additional, De Braganca, K., additional, Yohay, K., additional, Wolff, J. E., additional, Kwiecien, R., additional, Rutkowski, S., additional, Pietsch, T., additional, Faldum, A., additional, Kortmann, R.-D., additional, Kramm, C., additional, Fouladi, M., additional, Olson, J., additional, Stewart, C., additional, Kocak, M., additional, Wagner, L., additional, Packer, R., additional, Gururangan, S., additional, Blaney, S., additional, Pollack, I., additional, Demuth, T., additional, Gilbertson, R., additional, Powell, M. K., additional, Klement, G. L., additional, Roffidal, T., additional, and Fonkem, E., additional
- Published
- 2012
- Full Text
- View/download PDF
10. PEDIATRICS CLINICAL RESEARCH
- Author
-
Murray, J. C., primary, Rainusso, N., additional, Roberts, R. A., additional, Gomez, A. M., additional, Egler, R., additional, Russell, H., additional, Okcu, M. F., additional, Gururangan, S., additional, Fangusaro, J., additional, Young-Poussaint, T., additional, Lesh, S., additional, Onar, A., additional, Gilbertson, R., additional, Packer, R., additional, McLendon, R., additional, Friedman, H. S., additional, Boyett, J., additional, Kun, L. E., additional, Venkatramani, R., additional, Haley, K., additional, Gilles, F., additional, Sposto, R., additional, Ji, L., additional, Olshefski, R., additional, Garvin, J., additional, Tekautz, T., additional, Kennedy, G., additional, Rassekh, R., additional, Moore, T., additional, Gardner, S., additional, Allen, J., additional, Shore, R., additional, Moertel, C., additional, Atlas, M., additional, Lasky, J., additional, Finlay, J., additional, Valera, E. T., additional, Brassesco, M. S., additional, Scrideli, C. A., additional, Oliveira, R. S., additional, Machado, H. R., additional, Tone, L. G., additional, Finlay, J. L., additional, Kreimer, S., additional, Dagri, J., additional, Grimm, J., additional, Bluml, S., additional, Britt, B., additional, Dhall, G., additional, Brown, R. J., additional, Shah, A., additional, Kapoor, N., additional, Abdel-Azim, H., additional, Rao, A. A. N., additional, Wallace, D., additional, Gajjar, A., additional, Packer, R. J., additional, Pearlman, M. L., additional, Sadighi, Z., additional, Bingham, R., additional, Vats, T., additional, Khatua, S., additional, Ko, R. H., additional, O'Neil, S., additional, Lavey, R. S., additional, Davidson, T. B., additional, Tovar, J., additional, Wong, K., additional, Olch, A., additional, Murray, J. C., additional, Honeycutt, J. H., additional, Donahue, D. J., additional, Head, H. W., additional, Alles, A. J., additional, Ray, A., additional, Pearlman, M., additional, Baskin, J., additional, Qaddoumi, I., additional, Ahchu, M. S., additional, Alabi, S. F., additional, Arambu, I. C., additional, Castellanos, M., additional, Gamboa, Y., additional, Martinez, R., additional, Montero, M., additional, Ocampo, E., additional, Howard, S. C., additional, Broniscer, A., additional, Baker, S. D., additional, Baker, J. N., additional, Panandiker, A. P., additional, Onar-Thomas, A., additional, Chin, T. K., additional, Merchant, T. E., additional, Davidoff, A., additional, Kaste, S. C., additional, Stewart, C. F., additional, Espinoza, J., additional, Patel, N., additional, Jeffrey, A., additional, Torkildson, J., additional, Cornelius, A., additional, Bedros, A., additional, Etzl, M., additional, Pradhan, K., additional, Corbett, R., additional, Sullivan, M., additional, McGowage, G., additional, Puccetti, D., additional, Stein, D., additional, Jasty, R., additional, Antony, R., additional, Patel, M., additional, Wong, K. E., additional, Krieger, M., additional, McComb, G., additional, Sanchez-Lara, P. A., additional, Randolph, L. M., additional, Krieger, M. D., additional, Wu, S., additional, Panigrahy, A., additional, Shimada, H., additional, Erdreich-Epstein, A., additional, Puccetti, D. M., additional, Kennedy, T., additional, Salamat, S., additional, Bradfield, Y., additional, Park, H. J., additional, Yoon, J. H., additional, Ahn, H. S., additional, Shin, H. Y., additional, Kim, S. K., additional, Im, H. J., additional, Ra, Y. S., additional, Won, S. C., additional, Baek, H. J., additional, Sung, K. W., additional, Hah, J. O., additional, Lim, Y. T., additional, Lee, G. S., additional, Lee, Y. H., additional, Kim, H. S., additional, Park, J. K., additional, Kim, M. K., additional, Park, J. E., additional, Chung, N. G., additional, Choi, H. S., additional, Campen, C. J., additional, Fisher, P. G., additional, Ruge, M. I., additional, Simon, T., additional, Suchorska, B., additional, Lehrke, R., additional, Hamisch, C., additional, Koerber, F., additional, Treuer, H., additional, Berthold, F., additional, Sturm, V., additional, Voges, J., additional, Kirsch, M., additional, Lindner, C., additional, and Schackert, G., additional
- Published
- 2011
- Full Text
- View/download PDF
11. MEDICAL AND NEURO-ONCOLOGY
- Author
-
Prithviraj, G. K., primary, Sommers, S. R., additional, Jump, R. L., additional, Halmos, B., additional, Chambless, L. B., additional, Parker, S. L., additional, Hassam-Malani, L., additional, McGirt, M. J., additional, Thompson, R. C., additional, Hunter, K., additional, Chamberlain, M. C., additional, Le, E. M., additional, Lee, E. L. T., additional, Sadighi, Z. S., additional, Pearlman, M. L., additional, Slopis, J. M., additional, Vats, T. S., additional, Khatua, S., additional, DeVito, N. C., additional, Yu, M., additional, Chen, R., additional, Pan, E., additional, Cloughesy, T., additional, Raizer, J., additional, Drappatz, J., additional, Gerena-Lewis, M., additional, Rogerio, J., additional, Yacoub, S., additional, Desjardin, A., additional, Groves, M. D., additional, DeGroot, J., additional, Loghin, M., additional, Conrad, C. A., additional, Hess, K., additional, Ni, J., additional, Ictech, S., additional, Yung, W. A., additional, Porter, A. B., additional, Dueck, A. C., additional, Karlin, N. J., additional, Olson, J., additional, Silber, J., additional, Reiner, A. S., additional, Panageas, K. S., additional, Iwamoto, F. M., additional, Cloughesy, T. F., additional, Aldape, K. D., additional, Rivera, A. L., additional, Eichler, A. F., additional, Louis, D. N., additional, Paleologos, N. A., additional, Fisher, B. J., additional, Ashby, L. S., additional, Cairncross, J. G., additional, Roldan, G. B., additional, Wen, P. Y., additional, Ligon, K. L., additional, Shiff, D., additional, Robins, H. I., additional, Rocque, B. G., additional, Mason, W. P., additional, Weaver, S. A., additional, Green, R. M., additional, Kamar, F. G., additional, Abrey, L. E., additional, DeAngelis, L. M., additional, Jhanwar, S. C., additional, Rosenblum, M. K., additional, Lassman, A. B., additional, Cachia, D., additional, Alderson, L., additional, Moser, R., additional, Smith, T., additional, Yunus, S., additional, Saito, K., additional, Mukasa, A., additional, Narita, Y., additional, Tabei, Y., additional, Shinoura, N., additional, Shibui, S., additional, Saito, N., additional, Flechl, B., additional, Ackerl, M., additional, Sax, C., additional, Dieckmann, K., additional, Crevenna, R., additional, Widhalm, G., additional, Preusser, M., additional, Marosi, C., additional, Ay, C., additional, Dunkler, D., additional, Pabinger, I., additional, Zielinski, C., additional, Belongia, M., additional, Jogal, S., additional, Schlingensiepen, K.-H., additional, Bogdahn, U., additional, Stockhammer, G., additional, Mahapatra, A. K., additional, Venkataramana, N. K., additional, Oliushine, V., additional, Parfenov, V., additional, Poverennova, I., additional, Hau, P., additional, Jachimczak, P., additional, Heinrichs, H., additional, Mammoser, A. G., additional, Shonka, N. A., additional, de Groot, J. F., additional, Shibahara, I., additional, Sonoda, Y., additional, Kumabe, T., additional, Saito, R., additional, Kanamori, M., additional, Yamashita, Y., additional, Watanabe, M., additional, Ishioka, C., additional, Tominaga, T., additional, Silvani, A., additional, Gaviani, P., additional, Lamperti, E., additional, Botturi, A., additional, DiMeco, F., additional, Broggi, G., additional, Fariselli, L., additional, Solero, C. L., additional, Salmaggi, A., additional, Woyshner, E. A., additional, Shu, F., additional, Oh, Y. S., additional, Iganej, S., additional, Singh, G., additional, Vemuri, S. L., additional, Theeler, B. J., additional, Ellezam, B., additional, Gilbert, M. R., additional, Aoki, T., additional, Kobayashi, H., additional, Takano, S., additional, Nishikawa, R., additional, Nagane, M., additional, Muragaki, Y., additional, Sugiyama, K., additional, Kuratsu, J., additional, Matsutani, M., additional, Langford, L. A., additional, Puduvalli, V. K., additional, Shen, D., additional, Chen, Z.-p., additional, Zhang, J.-p., additional, Bedekar, D., additional, Rand, S., additional, Connelly, J., additional, Malkin, M., additional, Paulson, E., additional, Mueller, W., additional, Schmainda, K., additional, Gallego, O., additional, Benavides, M., additional, Segura, P. P., additional, Balana, C., additional, Gil, M., additional, Berrocal, A., additional, Reynes, G., additional, Garcia, J. L., additional, Murata, P., additional, Bague, S., additional, Quintana, M. J., additional, Vasishta, V. G., additional, Kobayashi, K., additional, Tanaka, M., additional, Tsuchiya, K., additional, Shiokawa, Y., additional, Bavle, A. A., additional, Ayyanar, K., additional, Prado, M. P., additional, Hess, K. R., additional, Liu, V., additional, de Groot, J., additional, Loghin, M. E., additional, Colman, H., additional, Levin, V. A., additional, Alfred Yung, W. K., additional, Hackney, J. R., additional, Palmer, C. A., additional, Markert, J. M., additional, Cure, J., additional, Riley, K. O., additional, Fathallah-Shaykh, H., additional, Nabors, L. B., additional, Saria, M. G., additional, Corle, C., additional, Hu, J., additional, Rudnick, J., additional, Phuphanich, S., additional, Mrugala, M. M., additional, Lee, L. K., additional, Fu, B. D., additional, Bota, D. A., additional, Kim, R. Y., additional, Brown, T., additional, Feely, H., additional, Hu, A., additional, Lee, J. W., additional, Carter, B., additional, Kesari, S., additional, Kong, X.-T., additional, Sparagana, S., additional, Belousova, E., additional, Jozwiak, S., additional, Korf, B., additional, Frost, M., additional, Kuperman, R., additional, Kohrman, M., additional, Witt, O., additional, Wu, J., additional, Flamini, R., additional, Jansen, A., additional, Curtalolo, P., additional, Thiele, E., additional, Whittemore, V., additional, De Vries, P., additional, Ford, J., additional, Shah, G., additional, Cauwel, H., additional, Edrich, P., additional, Sahmoud, T., additional, Franz, D., additional, Khasraw, M., additional, Brown, C., additional, Ashley, D. M., additional, Rosenthal, M. A., additional, Jiang, X., additional, Mou, Y. g., additional, Chen, Z. p., additional, Oh, M., additional, kim, E., additional, Chang, J., additional, Juratli, T. A., additional, Kirsch, M., additional, Schackert, G., additional, Krex, D., additional, Wang, M., additional, Stupp, R., additional, Hegi, M., additional, Jaeckle, K. A., additional, Armstrong, T. S., additional, Wefel, J. S., additional, Won, M., additional, Blumenthal, D. T., additional, Mahajan, A., additional, Schultz, C. J., additional, Erridge, S. C., additional, Brown, P. D., additional, Chakravarti, A., additional, Curran, W. J., additional, Mehta, M. P., additional, Hofland, K. F., additional, Hansen, S., additional, Sorensen, M., additional, Schultz, H., additional, Muhic, A., additional, Engelholm, S., additional, Ask, A., additional, Kristiansen, C., additional, Thomsen, C., additional, Poulsen, H. S., additional, Lassen, U. N., additional, Zalatimo, O., additional, Weston, C., additional, Zoccoli, C., additional, Glantz, M., additional, Rahmanuddin, S., additional, Shiroishi, M. S., additional, Cen, S. Y., additional, Jones, J., additional, Chen, T., additional, Pagnini, P., additional, Go, J., additional, Lerner, A., additional, Gomez, J., additional, Law, M., additional, Ram, Z., additional, Wong, E. T., additional, Gutin, P. H., additional, Bobola, M. S., additional, Alnoor, M., additional, Silbergeld, D. L., additional, Rostomily, R. C., additional, Silber, J. R., additional, Martha, N., additional, Jacqueline, S., additional, Thaddaus, G., additional, Daniel, P., additional, Hans, M., additional, Armin, M., additional, Eugen, T., additional, Gunther, S., additional, Hutterer, M., additional, Tseng, H.-M., additional, Zoccoli, C. M., additional, Patel, A., additional, Rizzo, K., additional, Sheehan, J. M., additional, Sumrall, A. L., additional, Vredenburgh, J. J., additional, Desjardins, A., additional, Reardon, D. A., additional, Friiedman, H. S., additional, Peters, K. B., additional, Taylor, L. P., additional, Stewart, M., additional, Blondin, N. A., additional, Baehring, J. M., additional, Foote, T., additional, Laack, N., additional, Call, J., additional, Hamilton, M. G., additional, Walling, S., additional, Eliasziw, M., additional, Easaw, J., additional, Shirsat, N. V., additional, Kundar, R., additional, Gokhale, A., additional, Goel, A., additional, Moiyadi, A. A., additional, Wang, J., additional, Mutlu, E., additional, Oyan, A., additional, Yan, T., additional, Tsinkalovsky, O., additional, Jacobsen, H. K., additional, Talasila, K. M., additional, Sleire, L., additional, Pettersen, K., additional, Miletic, H., additional, Andersen, S., additional, Mitra, S., additional, Weissman, I., additional, Li, X., additional, Kalland, K.-H., additional, Enger, P. O., additional, Sepulveda, J., additional, Belda, C., additional, Sitt, R., additional, Phishniak, L., additional, Bokstein, F., additional, Philippe, M., additional, Carole, C., additional, Andre, M. d. P., additional, Marylin, B., additional, Olivier, C., additional, L'Houcine, O., additional, Dominique, F.-B., additional, Isabelle, N.-M., additional, Frederic, F., additional, Stephane, F., additional, Henry, D., additional, Errico, M. A., additional, Kunschner, L. J., additional, Soffietti, R., additional, Trevisan, E., additional, Ruda, R., additional, Bertero, L., additional, Bosa, C., additional, Fabrini, M. G., additional, Lolli, I., additional, Jalali, R., additional, Julka, P. K., additional, Anand, A. K., additional, Bhavsar, D., additional, Singhal, N., additional, Naik, R., additional, John, S., additional, Mathew, B. S., additional, Thaipisuttikul, I., additional, Graber, J., additional, Shirinian, M., additional, Fontebasso, A. M., additional, Jacob, K., additional, Gerges, N., additional, Montpetit, A., additional, Nantel, A., additional, Albrecht, S., additional, Jabado, N., additional, Shah, K., additional, Di, K., additional, Linskey, M., additional, Thon, N., additional, Eigenbrod, S., additional, Kreth, S., additional, Lutz, J., additional, Tonn, J.-C., additional, Kretzschmar, H., additional, Peraud, A., additional, Kreth, F.-W., additional, Muggeri, A. D., additional, Alderuccio, J. P., additional, Diez, B. D., additional, Jiang, P., additional, Chao, Y., additional, Gallagher, M., additional, Kim, R., additional, Pastorino, S., additional, Fogal, V., additional, Rudnick, J. D., additional, Bresee, C., additional, Rogatko, A., additional, Sakowsky, S., additional, Franco, M., additional, Lim, S., additional, Lopez, A., additional, Yu, L., additional, Ryback, K., additional, Tsang, V., additional, Lill, M., additional, Steinberg, A., additional, Sheth, R., additional, Grimm, S., additional, Helenowski, I., additional, Rademaker, A., additional, Nunes, F. P., additional, Merker, V., additional, Jennings, D., additional, Caruso, P., additional, Muzikansky, A., additional, Stemmer-Rachamimov, A., additional, Plotkin, S., additional, Spalding, A. C., additional, Vitaz, T. W., additional, Sun, D. A., additional, Parsons, S., additional, Welch, M. R., additional, Omuro, A., additional, Beal, K., additional, Correa, D., additional, Chan, T., additional, DeAngelis, L., additional, Gavrilovic, I., additional, Nolan, C., additional, Hormigo, A., additional, Kaley, T., additional, Mellinghoff, I., additional, Grommes, C., additional, Panageas, K., additional, Reiner, A., additional, Barradas, R., additional, Abrey, L., additional, Gutin, P., additional, Lee, S. Y., additional, Slagle-Webb, B., additional, Glantz, M. J., additional, Connor, J. R., additional, Schlimper, C. A., additional, Schlag, H., additional, Stoffels, G., additional, Weber, F., additional, Krueger, D. A., additional, Care, M. M., additional, Holland, K., additional, Agricola, K., additional, Tudor, C., additional, Byars, A., additional, Franz, D. N., additional, Rice, L., additional, Chandler, J., additional, Levy, R., additional, Muro, K., additional, Nayak, L., additional, Norden, A. D., additional, Kaley, T. J., additional, Thomas, A. A., additional, Fadul, C. E., additional, Meyer, L. P., additional, Lallana, E. C., additional, Gilbert, M., additional, Aldape, K., additional, De Groot, J., additional, Conrad, C., additional, Levin, V., additional, Groves, M., additional, Chris, P., additional, Puduvalli, V., additional, Nagpal, S., additional, Feroze, A., additional, Recht, L., additional, Rangarajan, H. G., additional, Kieran, M. W., additional, Scott, R. M., additional, Lew, S. M., additional, Firat, S. Y., additional, Segura, A. D., additional, Jogal, S. A., additional, Kumthekar, P. U., additional, Grimm, S. A., additional, Avram, M., additional, Patel, J., additional, Kaklamani, V., additional, McCarthy, K., additional, Cianfrocca, M., additional, Gradishar, W., additional, Mulcahy, M., additional, Von Roenn, J., additional, Galanis, E., additional, Anderson, S. K., additional, Lafky, J. M., additional, Kaufmann, T. J., additional, Uhm, J. H., additional, Giannini, C., additional, Kumar, S. K., additional, Northfelt, D. W., additional, Flynn, P. J., additional, Buckner, J. C., additional, Omar, A. I., additional, Schiff, D., additional, Delios, A., additional, Jakubowski, A., additional, Melguizo-Gavilanes, I., additional, Qiao, W., additional, Wang, X., additional, Hashemi-Sadraei, N., additional, Bawa, H., additional, Rahmathulla, G., additional, Patel, M., additional, Elson, P., additional, Stevens, G., additional, Peereboom, D., additional, Vogelbaum, M., additional, Weil, R., additional, Barnett, G., additional, Ahluwalia, M. S., additional, Alvord, E. C., additional, Rockne, R. C., additional, Rockhill, J. K., additional, Rostomily, R., additional, Lai, A., additional, Wardlaw, J., additional, Spence, A. M., additional, Swanson, K. R., additional, Zadeh, G., additional, Alahmadi, H., additional, Wilson, J., additional, Gentili, F., additional, Beumer, J. J., additional, Wright, J., additional, Takebe, N., additional, Gaur, R., additional, Werner-Wasik, M., additional, Gupta, A. J., additional, Campos-Gines, A., additional, Le, K., additional, Arango, C., additional, Richards, M., additional, Landeros, M., additional, Juan, H., additional, Chang, J. H., additional, Kim, J. S., additional, Cho, J. H., additional, Seo, C. O., additional, Baldock, A. L., additional, Rockne, R., additional, Canoll, P., additional, Born, D., additional, Yagle, K., additional, Alexandru, D., additional, Bota, D., additional, Linskey, M. E., additional, Nabeel, S., additional, Raval, S. N., additional, Rosenow, J., additional, Bredel, M., additional, New, P. Z., additional, Plotkin, S. R., additional, Supko, J. G., additional, Curry, W. T., additional, Chi, A. S., additional, Gerstner, E. R., additional, Batchelor, T. T., additional, Hashemi, N., additional, Chao, S. T., additional, Weil, R. J., additional, Suh, J. H., additional, Vogelbaum, M. A., additional, Stevens, G. H., additional, Barnett, G. H., additional, Corwin, D., additional, Holdsworth, C., additional, Stewart, R., additional, Swanson, K., additional, Graber, J. J., additional, Anderson, A. R., additional, Jeyapalan, S., additional, Goldman, M., additional, Boxerman, J., additional, Donahue, J., additional, Elinzano, H., additional, Evans, D., additional, O'Connor, B., additional, Puthawala, M. Y., additional, Oyelese, A., additional, Cielo, D., additional, Blitstein, M., additional, Dargush, M., additional, Santaniello, A., additional, Constantinou, M., additional, DiPetrillo, T., additional, Safran, H., additional, Halpin, C., additional, Barker, F. G., additional, Maher, E. A., additional, Ganji, S., additional, DeBerardinis, R., additional, Hatanpaa, K., additional, Rakheja, D., additional, Yang, X.-L., additional, Mashimo, T., additional, Raisanen, J., additional, Madden, C., additional, Mickey, B., additional, Malloy, C., additional, Bachoo, R., additional, Choi, C., additional, Ranjan, T., additional, Yono, N., additional, Han, S. J., additional, Sun, M., additional, Berger, M. S., additional, Aghi, M., additional, Gupta, N., additional, and Parsa, A. T., additional
- Published
- 2011
- Full Text
- View/download PDF
12. Effect of Ball Size and Ball to Powder Ratio Variation on Crystallite Size and Formation of Nanocrystalline Materials in Planetary Ball Mill
- Author
-
Salili, S. M., primary, Ataie, A., additional, Sadighi, Z., additional, Aslan, Muhammed Hasan, additional, Oral, Ahmet Yayuz, additional, Özer, Mehmet, additional, and Çaglar, Süleyman Hikmet, additional
- Published
- 2011
- Full Text
- View/download PDF
13. Effect of Mechanical Activation in the Processing of Nano-Structured La[sub 0.8]Ba[sub 0.2]MnO[sub 3]
- Author
-
Sadighi, Z., primary, Ataie, A., additional, Salili, S. M., additional, Aslan, Muhammed Hasan, additional, Oral, Ahmet Yayuz, additional, Özer, Mehmet, additional, and Çaglar, Süleyman Hikmet, additional
- Published
- 2011
- Full Text
- View/download PDF
14. Effect of Mechanical Activation in the Processing of Nano-Structured La0.8Ba0.2MnO3.
- Author
-
Sadighi, Z., Ataie, A., and Salili, S. M.
- Subjects
- *
MECHANICAL behavior of materials , *ACTIVATION (Chemistry) , *NANOSTRUCTURED materials , *LANTHANUM compounds , *INORGANIC synthesis , *HEAT treatment of metals , *MECHANICAL alloying , *X-ray diffraction , *PHASE equilibrium - Abstract
Nano-structured La0.8Ba0.2MnO3 (LBM3) proveskite was synthesized using a planetary high energy ball mill up to 10 h and subsequent heat treatment. XRD, SEM, and DTA/TGA techniques were used to evaluate the powder particle characteristics. XRD results showed the characteristic peaks of the starting materials however by increasing the milling time up to 5 h only La2O3 phase was detected. Further increase in the milling resulted in the complete amorphization of the samples up to 10 h. SEM results showed strongly agglomerated structure of LBM3. DTA/TGA results of 2 h-milled sample showed three endothermic peaks and a remarkable reduction of weight that may attribute to the calcinations. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Effect of Mechanical Activation in the Processing of Nano-Structured La0.8Ba0.2MnO3.
- Author
-
Sadighi, Z., Ataie, A., and Salili, S. M.
- Subjects
MECHANICAL behavior of materials ,ACTIVATION (Chemistry) ,NANOSTRUCTURED materials ,LANTHANUM compounds ,INORGANIC synthesis ,HEAT treatment of metals ,MECHANICAL alloying ,X-ray diffraction ,PHASE equilibrium - Abstract
Nano-structured La
0.8 Ba0.2 MnO3 (LBM3) proveskite was synthesized using a planetary high energy ball mill up to 10 h and subsequent heat treatment. XRD, SEM, and DTA/TGA techniques were used to evaluate the powder particle characteristics. XRD results showed the characteristic peaks of the starting materials however by increasing the milling time up to 5 h only La2 O3 phase was detected. Further increase in the milling resulted in the complete amorphization of the samples up to 10 h. SEM results showed strongly agglomerated structure of LBM3. DTA/TGA results of 2 h-milled sample showed three endothermic peaks and a remarkable reduction of weight that may attribute to the calcinations. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
16. Effects of heat treatment on the characteristics of mechano-thermally synthesized nano-structured La0.8Ba0.2MnO3 powder.
- Author
-
Sadighi, Z., Ataie, A., and Barati, M.R.
- Subjects
- *
HEAT treatment , *NANOSTRUCTURED materials , *LANTHANUM compounds , *MANGANESE oxides , *INORGANIC synthesis , *POWDER metallurgy , *BALL mills - Abstract
In this study, barium-doped lanthanum manganite, La0.8Ba0.2MnO3 was synthesized via a mechano-thermal route employing high energy ball milling followed by heat treatment. The structural evolution, morphology and thermal behavior of the powders were evaluated using X-ray diffraction, high resolution scanning electron microscope, and differential thermal analysis/thermo-gravimetric analysis, respectively. The magnetic properties were investigated using an AC susceptometer. X-ray diffraction results revealed the formation of a single phase La0.8Ba0.2MnO3 perovskite with a mean crystallite size of 13nm in a 30h milled sample after the heat treatment at 700°C for 1h. The images of the high resolution scanning electron microscope showed the mean particle size of 350nm for 5h heat treated sample at 1200°C and a change from round-type to multifaceted morphology by increasing the heat treatment temperature. AC susceptibility results showed that increasing heat treatment temperature and time to 1300°C and 5h, respectively, leads to 60% increase in Curie temperature. The paramagnetic–ferromagnetic transition width decreases by increasing the heat treatment temperature and time. The samples heat treated at 900 and 1100°C for 1h exhibited reentered spin-glass behavior which is probably because of the deficiency of Ba content. The milled sample after the heat treatment at 1300°C exhibits metal–insulator behavior and metal–insulator transition temperature (TM–I) is highly dependent on the applied magnetic field. The maximum TM–I shifts from 230K at zero magnetic field towards room temperature near 244K with applying the external magnetic field of 10kOe. It was found that the milled sample after heat treatment at 1300°C exhibits the high MR of 18% at 300K under H=10kOe. This exceptional MR at room temperature suggests this material as a most promising nano-structured CMR material. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)
- Author
-
Montazeri Ali, Mohagheghi Mohammad, Sadighi Sanambar, and Sadighi Zahra
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Health related quality of life (HRQOL) is an important outcome after treatment for upper gastrointestinal carcinoma. This study aimed to compare HRQOL in patients with advanced gastric cancer (GC) receiving either a standard or an experimental treatment. Methods Seventy-one patients have been treated in Cancer Institute (Tehran, Iran) with docetaxel, cisplatin, 5 FU (TCF) or epirubicin, cisplatin, 5-FU (ECF) and were followed from Jan 2002 to Jan 2005. End points were response rate, HRQOL and survival. HRQOL was assessed using the EORCT QLQ-C30 at baseline and after the third cycle of chemotherapy. Results The baseline HRQOL scores were comparable between two groups. After treatment improvement was seen in a number of items and domains except for cognitive functioning, and diarrhoea. Pain decreased and physical functioning improved in both groups. However, only the TCF group showed statistically and clinically meaningful improvement in global QOL (P = 0.001). Surgical and pathologic response was better with TCF but there was no difference in survival rate between two groups. Conclusion Docetaxel based treatment (TCF) showed better palliation and improvement of global QOL as compared with epirubicin based treatment (ECF). However, it seems that regardless of treatment offered, effective chemotherapy was the most important factor affecting QOL in these patients.
- Published
- 2006
- Full Text
- View/download PDF
18. Characterization of mechano-thermally synthesized Curie temperature-adjusted La{sub 0.8}Sr{sub 0.2}MnO{sub 3} nanoparticles coated with (3-aminopropyl) triethoxysilane
- Author
-
Sadighi, Z. [School of Metallurgy and Materials Engineering, College of Engineering, University of Tehran, Tehran (Iran, Islamic Republic of)]
- Published
- 2015
- Full Text
- View/download PDF
19. Immunotherapy-Related Neurotoxicity in the Central Nervous System of Children with Cancer.
- Author
-
He J, Connors J, Meador A, Xu S, Meador H, Jiang H, Fueyo J, Gomez-Manzano C, Friedman GK, Zaky W, Sadighi Z, Slopis JM, and Ahmad AH
- Abstract
Significant gaps remain in our understanding of immunotherapy-related neurotoxicity in pediatric patients, largely because much of our knowledge comes from studies in adults. Accurately identifying the adverse effects of immunotherapy in children is also challenging, owing to variations in terminology and grading systems. Moreover, the manifestation of immunotherapy-related neurotoxicity differs greatly across different diseases, various modalities, dosages, and delivery methods. Combining immunotherapy with other treatments might improve outcomes but introduces new complexities and potential for increased toxicities. Additionally, pediatric patients with intracranial malignancy have unique responses to immunotherapies and distinct neurotoxicity compared to those with extracranial malignancy. Consequently, we must enhance our understanding of the pathophysiology, prevalence, severity, and management of immunotherapy's neurotoxic effects in this vulnerable group. This review consolidates the current knowledge of immunotherapy-related neurotoxicity in pediatric oncology, highlighting various types of neurotoxicity including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and tumor inflammation-associated neurotoxicity (TIAN), among others. Furthermore, we examine the unique features of neurotoxicity associated with adoptive cellular therapy (ACT), antibody-based therapies, immune checkpoint inhibitors (ICIs), oncolytic viruses (OV), and cancer vaccines., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
20. ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
- Author
-
Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, Weber MD, Lokku A, Smith LM, Foreman NK, Hajjar FM, McNall-Knapp RY, Weintraub L, Antony R, Franson AT, Meade J, Schiff D, Walbert T, Ambady P, Bota DA, Campen CJ, Kaur G, Klesse LJ, Maraka S, Moots PL, Nevel K, Bornhorst M, Aguilar-Bonilla A, Chagnon S, Dalvi N, Gupta P, Khatib Z, Metrock LK, Nghiemphu PL, Roberts RD, Robison NJ, Sadighi Z, Stapleton S, Babovic-Vuksanovic D, and Gershon TR
- Abstract
Purpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults., Methods: ReNeu is an open-label, multicenter, pivotal, phase IIb trial of mirdametinib in 58 adults (≥18 years of age) and 56 children (2 to 17 years of age) with NF1-PN causing significant morbidities. Patients received mirdametinib capsules or tablets for oral suspension (2 mg/m
2 twice daily, maximum 4 mg twice daily), regardless of food intake, in 3 weeks on/1 week off 28-day cycles. The primary end point was confirmed objective response rate (ORR; proportion of patients with a ≥20% reduction of target PN volume from baseline on consecutive scans during the 24-cycle treatment phase) assessed by blinded independent central review (BICR) of volumetric magnetic resonance imaging., Results: Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses during long-term follow-up. Median (range) target PN volumetric best response was -41% (-90 to 13) in adults and -42% (-91 to 48) in children. Both cohorts reported significant and clinically meaningful improvement in patient- or parent proxy-reported outcome measures of worst tumor pain severity, pain interference, and health-related quality of life (HRQOL) that began early and were sustained during treatment. The most commonly reported treatment-related adverse events were dermatitis acneiform, diarrhea, and nausea in adults and dermatitis acneiform, diarrhea, and paronychia in children., Conclusion: In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.- Published
- 2024
- Full Text
- View/download PDF
21. Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors.
- Author
-
Hummel L, Ameri M, Alqahtani S, Sadighi Z, and Al-Zubidi N
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Male, Young Adult, Benzimidazoles, Eye Diseases drug therapy, Eye Diseases genetics, Incidence, MAP Kinase Kinase Kinases antagonists & inhibitors, Pyridones, Pyrimidinones, Retrospective Studies, Neurofibromatosis 1 complications, Neurofibromatosis 1 drug therapy, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use
- Abstract
MEK inhibitors (MEKi) represent innovative and promising treatments for managing manifestations of neurofibromatosis type 1 (NF1). To mitigate potential ophthalmic side effects, such as MEKi-associated retinopathy (MEKAR), patients undergoing MEKi therapy routinely receive ophthalmology evaluations. Our study aims to assess the necessity of this regular screening within a predominantly pediatric NF1 population by examining the occurrence of ocular adverse events (OAE). A retrospective study evaluated 45 NF1 patients receiving MEKi. Inclusion criteria included baseline and follow-up examinations following the initiation of MEKi therapy. At each assessment, a comprehensive eye evaluation was performed, comprising a dilated fundus examination, ocular coherence tomography of the macula and nerve fiber layer, and Humphrey visual field testing. Twenty-six patients, with an average age of 13 years (range 2-23 years) and an average follow-up duration of 413 days were included in the analysis. Three different MEKi were used: selumetinib (77%), trametinib (23%), and mirdametinib (4%). None of the patients experienced retinopathy at any point during the study. Some patients had pre-existing optic neuropathies (27%), but no instances of nerve changes occurred after commencing MEKi therapy. Four patients (15%) exhibited symptoms of dry eye, all of which were effectively managed with topical lubrication.
- Published
- 2024
- Full Text
- View/download PDF
22. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
- Author
-
Peacock BC, Tripathy S, Hanania HL, Wang HY, Sadighi Z, and Patel AB
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Male, Young Adult, Drug Eruptions etiology, Follow-Up Studies, Neurofibroma, Plexiform drug therapy, Neurofibroma, Plexiform pathology, Prognosis, Retrospective Studies, Neurofibromatosis 1 drug therapy, Protein Kinase Inhibitors adverse effects
- Abstract
Purpose: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder which commonly causes neoplasms leading to disfigurement or dysfunction. Mitogen-activated protein kinase inhibitors (MEKi) are generally well-tolerated treatments which target neural tumor progression in patients with NF1. However, cutaneous adverse events (CAEs) are common and may hinder patients' abilities to remain on treatment, particularly in children. We aim to characterize CAEs secondary to MEKi treatment in pediatric and young adult patients with NF1., Methods: We reviewed institutional medical records of patients under 30 years with a diagnosis of "NF1," "NF2," or "other neurofibromatoses" on MEKi therapy between January 1, 2019 and June 1, 2022. We recorded the time-to-onset, type, and distribution of CAEs, non-cutaneous adverse events (AEs), AE management, and tumor response., Results: Our cohort consisted of 40 patients with NF1 (median age, 14 years). Tumor types included low-grade gliomas (51%) and plexiform neurofibromas (38%). MEKi used included selumetinib (69%), trametinib (25%), and mirdametinib (6%). A total of 74 CAEs occurred, with 28 cases of acneiform rash (38%). Other common CAEs were paronychia, seborrheic dermatitis, eczema, xerosis, and oral mucositis. The most common treatments included oral antibiotics and topical corticosteroids. Most patients had clinical (stable or improved) tumor response (71%) while 29% had tumor progression while on a MEKi. There was no significant association between CAE presence and tumor response (p = 0.39)., Conclusions: Improvement in characterization of MEKi toxicities and their management is important to develop treatment guidelines for pediatric and young adult patients with NF1 on MEKi therapy., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
23. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
- Author
-
Sarkar S, Throckmorton W, Bingham R, Msaouel P, Genovese G, Slopis J, Rao P, Sadighi Z, and Herzog CE
- Subjects
- Female, Humans, Phenotype, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Kidney Neoplasms genetics, Kidney Neoplasms pathology, Meningeal Neoplasms genetics, Meningioma genetics, Neurofibromatosis 2 complications, Neurofibromatosis 2 genetics
- Abstract
We present, to our knowledge, the first reported case of germline neurofibromatosis Type 2 (NF2) associated with renal cell carcinoma unclassified with medullary phenotype (RCCU-MP) with somatic loss by immunohistochemistry of the SMARCB1 tumor suppressor gene located centromeric to NF2 on chromosome 22q. Our patient is a 15-year-old with germline neurofibromatosis Type 2 (NF2) confirmed by pathogenic mutation of c.-854-??46+??deletion. Her NF2 history is positive for a right optic nerve sheath meningioma, CNIII schwannoma requiring radiation therapy and post gross total resection of right frontotemporal anaplastic meningioma followed by radiation. At age 15 she developed new onset weight loss and abdominal pain due to RCCU-MP. Hemoglobin electrophoresis was negative for sickle hemoglobinopathy. Chemotherapy (cisplatin, gemcitabine and paclitaxel) was initiated followed by radical resection. Given the unique renal pathology of a high grade malignancy with loss of SMARCB1 expression via immunohistochemistry, and history of meningioma with MLH1 loss of expression and retained expression of PMS2, MSH2 and MSH6, further germline genetic testing was sent for SMARCB1 and mismatch repair syndromes. Germline testing was negative for mutation in SMARCB1 . Therefore, this is the first reported case of RCCU-MP associated with germline NF2 mutation. This suggests the importance of closer surveillance in the adolescent and young adult population with NF2 with any suspicious findings of malignancy outside of the usual scope of practice with NF2.
- Published
- 2023
- Full Text
- View/download PDF
24. Contrast Enhancement Patterns in Pediatric Glioblastomas.
- Author
-
Pokhylevych H, Khose S, Gule-Monroe MK, Chen MM, Fuller G, Gruschkus SK, Sadighi Z, Zaky W, Sandberg DI, McGovern SL, and Johnson JM
- Subjects
- Humans, Child, Magnetic Resonance Imaging methods, Prognosis, Retrospective Studies, Glioblastoma diagnostic imaging, Glioblastoma pathology, Brain Neoplasms pathology
- Abstract
Background and Purpose: Brain tumors are the most common cause of cancer-related deaths among the pediatric population. Among these, pediatric glioblastomas (GBMs) comprise 2.9% of all central nervous system tumors and have a poor prognosis. The purpose of this study is to determine whether the imaging findings can be a prognostic factor for survival in children with GBMs., Materials and Methods: The imaging studies and clinical data from 64 pediatric patients with pathology-proven GBMs were evaluated. Contrast enhancement patterns were classified into focal, ring-like, and diffuse, based on preoperative postcontrast T1-weighted magnetic resonance images. We used the Kaplan-Meier method and Cox proportional hazard regression to evaluate the prognostic value of imaging findings., Results: Patients with ring-enhanced GBMs who underwent gross total resection or subtotal resection were found to have a significantly shorter progression-free survival ( P = 0.03) comparing with other enhancing and nonenhancing glioblastomas., Conclusions: In this study, we analyzed survival factors in children with pediatric glioblastomas. In the group of patients who underwent gross total resection or subtotal resection, those patients with focal-enhanced GBMs had significantly longer progression-free survival ( P = 0.03) than did those with other types of enhancing GBMs (diffuse and ring-like)., Competing Interests: The authors declare no conflict of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
25. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
- Author
-
Bowers DC, Verbruggen LC, Kremer LCM, Hudson MM, Skinner R, Constine LS, Sabin ND, Bhangoo R, Haupt R, Hawkins MM, Jenkinson H, Khan RB, Klimo P Jr, Pretorius P, Ng A, Reulen RC, Ronckers CM, Sadighi Z, Scheinemann K, Schouten-van Meeteren N, Sugden E, Teepen JC, Ullrich NJ, Walter A, Wallace WH, Oeffinger KC, Armstrong GT, van der Pal HJH, and Mulder RL
- Subjects
- Adolescent, Central Nervous System Neoplasms diagnosis, Child, Early Detection of Cancer, Humans, Young Adult, Cancer Survivors, Central Nervous System Neoplasms etiology, Practice Guidelines as Topic
- Abstract
Exposure to cranial radiotherapy is associated with an increased risk of subsequent CNS neoplasms among childhood, adolescent, and young adult (CAYA) cancer survivors. Surveillance for subsequent neoplasms can translate into early diagnoses and interventions that could improve cancer survivors' health and quality of life. The practice guideline presented here by the International Late Effects of Childhood Cancer Guideline Harmonization Group was developed with an evidence-based method that entailed the gathering and appraisal of published evidence associated with subsequent CNS neoplasms among CAYA cancer survivors. The preparation of these guidelines showed a paucity of high-quality evidence and highlighted the need for additional research to inform survivorship care. The recommendations are based on careful consideration of the evidence supporting the benefits, risks, and harms of the surveillance interventions, clinical judgment regarding individual patient circumstances, and the need to maintain flexibility of application across different health-care systems. Currently, there is insufficient evidence to establish whether early detection of subsequent CNS neoplasms reduces morbidity and mortality, and therefore no recommendation can be formulated for or against routine MRI surveillance. The decision to start surveillance should be made by the CAYA cancer survivor and health-care provider after careful consideration of the potential harms and benefits of surveillance for CNS neoplasms, including meningioma., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
- Author
-
Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, Petropoulos D, Slopis JM, Sadighi Z, and Khazal S
- Abstract
The Cornell Assessment for Pediatric Delirium (CAPD) was first proposed by the Pediatric Acute Lung Injury and Sepsis Investigators Network-Stem Cell Transplantation and Cancer Immunotherapy Subgroup and MD Anderson CARTOX joint working committees, for detection of immune effector cell associated neurotoxicity (ICANS) in pediatric patients receiving chimeric antigen receptor (CAR) T-cell therapy. It was subsequently adopted by the American Society for Transplantation and Cellular Therapy. The utility of CAPD as a screening tool for early diagnosis of ICANS has not been fully characterized. We conducted a retrospective study of pediatric and young adult patients (n=15) receiving standard-of-care CAR T-cell products. Cytokine release syndrome (CRS) and ICANS occurred in 87% and 40% of patients, respectively. ICANS was associated with significantly higher peaks of serum ferritin. A change in CAPD from a prior baseline was noted in 60% of patients with ICANS, 24-72 h prior to diagnosis of ICANS. The median change from baseline to maximum CAPD score of patients who developed ICANS versus those who did not was 13 versus 3, respectively (p=0.0004). Changes in CAPD score from baseline may be the earliest indicator of ICANS among pediatric and young adult patients which may warrant closer monitoring, with more frequent CAPD assessments., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Brown, Tambaro, Kohorst, Chi, Mahadeo, Tewari, Petropoulos, Slopis, Sadighi and Khazal.)
- Published
- 2021
- Full Text
- View/download PDF
27. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
- Author
-
Sun Y, Bailey CP, Sadighi Z, Zaky W, and Chandra J
- Subjects
- Animals, Child, Chromatin, Epigenesis, Genetic, ErbB Receptors, Histone Deacetylases, Humans, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Glioma drug therapy, Glioma genetics
- Abstract
Introduction: Supratentorial pediatric high-grade gliomas (pHGGs) are aggressive malignancies that lack effective treatment options. Deep genomic sequencing by multiple groups has revealed that the primary alterations unique to pHGGs occur in epigenetic and kinase genes. These mutations, fusions, and deletions present a therapeutic opportunity by use of small molecules targeting epigenetic modifiers and kinases that contribute to pHGG growth., Methods: Using a targeted search of the pre-clinical literature and clinicaltrials.gov for kinase and epigenetic pathways in pHGG, we collectively describe how these mechanisms are being targeted in pre-clinical animal models and in current clinical trials, as well as propose unexplored therapeutic possibilities for future investigations., Results: Relevant pHGG kinases are targetable by several FDA-approved or clinical-stage kinase inhibitors, including altered BRAF/MET/NTRK/ALK and wild-type PI3K/EGFR/PDGFR/VEGF/AXL. Epigenetic proteins implicated in pHGG are also clinically targetable and include histone erasers, writers and readers such as HDACs, demethylases LSD1/JMJD3, methyltransferase EZH2, chromatin reader bromodomains, and chromatin remodeler subunit BMI-1. Crosstalk between these pathways can occur involving kinases such as EGFR and AMPK interacting with epigenetic modifiers such as HDACs or EZH2. Single agent trial results of kinase inhibitors or epigenetic targets alone are underwhelming and hampered by poor pharmacokinetics, adaptive resistance, and broad inclusion criteria., Conclusions: The genetic and phenotypic diversity of pHGGs is now well characterized after large-scale sequencing studies on patient tissue. However, clinical treatment paradigms have not yet shifted in response to this information. Combination therapies targeting multiple kinases or epigenetic targets may hold more promise, especially if attempted in selected patient populations with hemispheric pHGG tumors and relevant targeted therapeutic biomarkers.
- Published
- 2020
- Full Text
- View/download PDF
28. Evaluating pediatric spinal low-grade gliomas: a 30-year retrospective analysis.
- Author
-
Carey SS, Sadighi Z, Wu S, Chiang J, Robinson GW, Ghazwani Y, Liu APY, Acharya S, Merchant TE, Boop FA, Gajjar A, and Qaddoumi I
- Subjects
- Adolescent, Child, Child, Preschool, Disease-Free Survival, Female, Glioma mortality, Glioma therapy, Humans, Infant, Infant, Newborn, Male, Retrospective Studies, Spinal Cord Neoplasms mortality, Spinal Cord Neoplasms therapy, Treatment Outcome, Glioma pathology, Spinal Cord Neoplasms pathology
- Abstract
Purpose: Most pediatric spinal tumors are low-grade gliomas (LGGs). Characterization of these tumors has been difficult given their heterogeneity and rare incidence. The objective was to characterize such tumors diagnosed at our institution., Methods: Spinal tumors diagnosed in our pediatric patients between 1984 and 2014 were reviewed retrospectively. Demographics, presentation, pathology, imaging, management, and sequelae were examined., Results: Forty patients had spinal LGG tumors, 24 (62%) of which were pilocytic astrocytomas. The most common initial presentations were pain (n = 15), partial extremity paralysis (n = 13), and ataxia (n = 11), with the diagnosis frequently delayed by months (median = 5.9 months, range 4 days-6.2 years). Twenty-nine patients had some tumor resection, and 8 required adjuvant therapy with chemotherapy (n = 4) or radiation (n = 4) post-resection. Ten other patients received only biopsy for histologic diagnosis, who were treated with chemotherapy (n = 4) or radiation (n = 5) post biopsy. Tumor progression was noted in 16 patients (2 after gross-total resection; 10, partial resection; and 4, biopsy). During the evaluation period, 3 patients died secondary to tumor progression. BRAF status could have shortened progression-free survival: patients with BRAFV600E mutations (n = 3) all experienced progression within 10 months. Long-term sequelae of the disease/treatment were mostly residual neurologic deficits (paresthesia, paralysis), chemotherapy-induced hearing loss, and scoliosis., Conclusions: Spinal LGG is a rare entity with significant long-term effects. Although surgery is the most common initial treatment option, more in-depth analysis of molecular biomarkers may improve stratification and prognostication.
- Published
- 2019
- Full Text
- View/download PDF
29. Nitrogen-doped graphene fiber webs for multi-battery energy storage.
- Author
-
Chong WG, Xiao F, Yao S, Cui J, Sadighi Z, Wu J, Ihsan-Ul-Haq M, Shao M, and Kim JK
- Abstract
Freestanding carbon-based electrodes with large surface areas and pore volumes are essential to fast ion transport and long-term energy storage. Many of the current porous carbon substrates are composed of particulates, making it difficult to form a self-supported structure. Herein, novel highly porous nitrogen-doped graphene fiber webs (N-GFWs) are prepared using a facile wet-spinning method. The wet chemical process facilitates simultaneous N-doping and surface wrinkling of graphene fibers in a one-pot process. The atomic structure and electrical conductivity of N-GFWs are tailored by tuning the degree of N-doping and thermal reduction for multi-battery charge storage in both lithium-oxygen batteries (LOBs) and lithium-sulfur batteries (LSBs). The N-GFW900 electrode presents an excellent electrocatalytic activity and the cathode with a high areal loading of 7.5 mg cm-2 delivers a remarkable areal capacity of 2 mA h cm-2 at 0.2 mA cm-2 for LOBs. The N-GFW700 interlayer with abundant oxygenated and nitrogen functional groups demonstrates effective entrapment of polysulfides in LSBs, delivering a much improved specific capacity after 200 cycles at 0.5C with a remarkable decay rate of 0.04%. The current approach paves the way for rational design of porous graphene-based electrodes, satisfying multifunctional requirements for high-energy storage applications.
- Published
- 2019
- Full Text
- View/download PDF
30. Metallic MoS 2 nanosheets: multifunctional electrocatalyst for the ORR, OER and Li-O 2 batteries.
- Author
-
Sadighi Z, Liu J, Zhao L, Ciucci F, and Kim JK
- Abstract
Lithium-oxygen batteries (LOBs) possess the highest theoretical specific density among all types of lithium batteries, making them ideal candidates to replace the current Li ion batteries for next-generation electric vehicle applications. However, designing highly active catalysts with high electronic conductivities to kinetically accelerate the sluggish oxygen reduction/evolution reactions (ORR/OER) is still a big challenge. This work was dedicated to developing two-dimensional (2D) trigonal phase MoS
2 (1T-MoS2 ) nanosheets as a highly active electrocatalyst for LOBs for the first time. Metallic 1T-MoS2 prepared via in situ liquid-redox intercalation and exfoliation was hybridized with functionalized carbon nanotubes (CNTs) to form freestanding, binder-free oxygen electrodes. The 1T-MoS2 /CNT electrode exhibited excellent electrochemical performances with a high reversible capacity of 500 mA h g-1 at a current density of 200 mA g-1 for more than 100 cycles owing to the catalytically active surfaces of 1T-MoS2 accessible by Li+ ions and O2 . Density functional theory (DFT) calculations identified the catalytically active basal planes in 1T-MoS2 during the ORR as well as the initial ORR path during LOB cycles. The results based on the rotational ring disk electrode (RRDE) experiments also supported the findings from the DFT calculations, where the 1T-MoS2 basal planes are active for both the ORR and OER, not the semiconducting hexagonal MoS2 (2H-MoS2 ) whose edges are only electrocatalytically active. This study sheds light on the use of metallic 1T-MoS2 as a multifunctional oxygen electrocatalyst for LOB applications with enhanced ORR and OER activities.- Published
- 2018
- Full Text
- View/download PDF
31. Mesoporous MnCo 2 S 4 nanosheet arrays as an efficient catalyst for Li-O 2 batteries.
- Author
-
Sadighi Z, Liu J, Ciucci F, and Kim JK
- Abstract
Ternary metal sulfides and ternary metal oxides have received much attention as potential electrodes for high performance rechargeable batteries. Herein, MnCo2S4 nanosheets are grown on carbon paper (MCS/CP) via facile electrodeposition followed by low temperature vulcanization for application in Li-O2 batteries for the first time. The electrochemical performance of freestanding, binder-free MCS/CP oxygen electrodes is compared with those prepared from MnCo2O4 nanosheets on CP (MCO/CP). The MCS/CP electrode delivers an extremely high initial specific capacity of 10 760 mA h g-1, twice that of MCO/CP. The former electrode sustains 96 cycles at an upper limit capacity of 500 mA h g-1 at 200 mA g-1, whereas the latter counterpart survives only a few cycles with a poor round trip efficiency. The superior performance of MCS/CP is in part proven by the four times higher electrical conductivity and 250% higher lithium diffusion coefficient than MCO/CP. In addition, the 3D interconnected web of 2D MCS nanosheets offers a few micrometer open voids to accommodate discharge products and a large surface area with internal mesopores providing abundant active sites. The density functional theory calculations reveal a lower adsorption energy for LiO2 on the surface of MCS than on MCO, which is responsible for the lower OER overpotential and the higher catalytic ability of MCS/CP. The predicted density of states signifies metallic properties of MCS in agreement with the high electrical conductivity of MCS/CP.
- Published
- 2018
- Full Text
- View/download PDF
32. Profound hearing loss following surgery in pediatric patients with posterior fossa low-grade glioma.
- Author
-
Ghazwani Y, Qaddoumi I, Bass JK, Wu S, Chiang J, Boop F, Gajjar A, and Sadighi Z
- Abstract
Background: Hearing loss may occur in patients with posterior fossa low-grade glioma who undergo surgery., Methods: We retrospectively reviewed 217 patients with posterior fossa low-grade glioma, including 115 for whom results of hearing tests performed after surgery and before chemotherapy or radiation therapy were available. We explored the association of UHL with age at diagnosis, sex, race, tumor location, extent of resection, posterior fossa syndrome, ventriculoperitoneal shunt placement, and histology., Results: Of the 115 patients, 15 (13.0%: 11 male, 6 black, 8 white, 1 multiracial; median age 7 years [range, 1.3-17.2 years]) had profound UHL after surgery alone or before receiving ototoxic therapy. Median age at tumor diagnosis was 6.8 years (range, 0.7-14.1 years), and median age at surgery was 6.8 years (range, 0.7-14.1 years). Patients with UHL had pathology characteristic of pilocytic astrocytoma (n = 10), ganglioglioma (n = 4), or low-grade astrocytoma (n = 1). Of these 15 patients, 4 underwent biopsy, 1 underwent gross total resection, 1 underwent near-total resection, and 9 underwent subtotal resection. UHL was more frequent in black patients than in white patients (OR 7.3, P = .007) and less frequent in patients who underwent gross total resection or near-total resection than in those who underwent subtotal resection (OR 0.11, P = .02)., Conclusions: Children undergoing surgery for posterior fossa low-grade glioma are at risk for UHL, which may be related to race or extent of resection. These patients should receive postoperative audiologic testing, as earlier intervention may improve outcomes.
- Published
- 2018
- Full Text
- View/download PDF
33. Diagnostic Clues to Human Herpesvirus 6 Encephalitis and Wernicke Encephalopathy After Pediatric Hematopoietic Cell Transplantation.
- Author
-
Sadighi Z, Sabin ND, Hayden R, Stewart E, and Pillai A
- Subjects
- Adolescent, Brain pathology, Child, Child, Preschool, Diagnosis, Differential, Encephalitis, Viral etiology, Encephalitis, Viral physiopathology, Encephalitis, Viral therapy, Female, Herpesvirus 6, Human, Humans, Magnetic Resonance Imaging, Male, Roseolovirus Infections etiology, Roseolovirus Infections physiopathology, Roseolovirus Infections therapy, Wernicke Encephalopathy etiology, Wernicke Encephalopathy physiopathology, Wernicke Encephalopathy therapy, Young Adult, Encephalitis, Viral diagnosis, Hematopoietic Stem Cell Transplantation adverse effects, Roseolovirus Infections diagnosis, Wernicke Encephalopathy diagnosis
- Abstract
Human herpesvirus 6 (HHV6) encephalitis and Wernicke encephalopathy are treatable yet frequently undiagnosed causes of encephalopathy in pediatric recipients of allogeneic and autologous hematopoietic cell transplantation. Here we review representative cases of both conditions to highlight specific and relevant neurologic features that prompted effective diagnosis and treatment. Two patients with confusion accompanied by seizures, memory changes, or specific visual hallucinations and HHV6 detectable by polymerase chain reaction (PCR) in cerebrospinal fluid had improvement in viral load with ganciclovir or foscarnet treatment. Two patients had confusion, ataxia, or ocular changes and low serum thiamine levels, which resolved with parenteral thiamine. In all cases, definitive diagnosis and treatment were facilitated by a high index of suspicion and search for specific pathognomonic neurologic deficits accompanying the confusional state. It is critical to clinically differentiate these 2 conditions from other common neurologic syndromes occurring after transplant, allowing potentially improved patient outcomes by prompt diagnosis and effective treatment., (© The Author(s) 2015.)
- Published
- 2015
- Full Text
- View/download PDF
34. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity.
- Author
-
Sadighi Z and Slopis J
- Subjects
- Astrocytoma diagnosis, Astrocytoma therapy, Brain Neoplasms diagnosis, Brain Neoplasms therapy, Cell Transformation, Neoplastic genetics, Cerebellar Neoplasms diagnosis, Cerebellar Neoplasms genetics, Cerebellar Neoplasms therapy, Child, Extracellular Signal-Regulated MAP Kinases genetics, Genes, Neurofibromatosis 1, Humans, Hypothalamic Neoplasms diagnosis, Hypothalamic Neoplasms genetics, Hypothalamic Neoplasms therapy, Molecular Targeted Therapy, Optic Chiasm, Optic Nerve Neoplasms diagnosis, Optic Nerve Neoplasms genetics, Optic Nerve Neoplasms therapy, Point Mutation genetics, Prognosis, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras), Transcriptional Activation genetics, ras Proteins genetics, Astrocytoma genetics, Brain Neoplasms genetics, Chromosome Aberrations, Genetic Heterogeneity
- Abstract
Pilocytic astrocytoma, the most common pediatric brain tumor, is a clinically and molecularly heterogeneous disease that occurs most often in the cerebellum and hypothalamic and chiasmatic regions. Classically, pilocytic astrocytomas are driven by the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Recently described genetic aberrations involving this pathway are critical for tumorigenesis. Tandem duplication of 7q34 encodes BRAF and produces several KIAA1549-BRAF novel oncogenic fusions. Activating point mutations of BRAF, such as BRAF (V600E), also lead to pilocytic astrocytoma. Loss of the NF1 gene allows hyperactivation of the oncogene KRAS. In this review, we discuss the current understanding of the novel molecular aberrations described in pilocytic astrocytomas and their clinical relevance for prognosis and treatment. The prognostic indications of these aberrations are discussed with regard to tumor location, tumor pathology, and patient age. A better understanding of the evolving molecular heterogeneity of pilocytic astrocytomas offers hope for developing molecularly targeted therapeutic armamentariums.
- Published
- 2013
- Full Text
- View/download PDF
35. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.
- Author
-
Sadighi Z, Vats T, and Khatua S
- Subjects
- Child, Preschool, Hedgehog Proteins genetics, Humans, Signal Transduction genetics, Wnt Proteins genetics, Cerebellar Neoplasms diagnosis, Cerebellar Neoplasms genetics, Cerebellar Neoplasms therapy, Medulloblastoma diagnosis, Medulloblastoma genetics, Medulloblastoma therapy, Pediatrics
- Abstract
Medulloblastoma is the most common malignant brain tumor of childhood, accounting for nearly 25% to 30% of primary central nervous system tumors in children younger than 18 years of age. Risk stratification into low and high risk categories has been based on age of clinical presentation, extent of postsurgical residual tumor, and disease dissemination. The World Health Organization (WHO) in 2007 recognized 5 histological subtypes as classic, anaplastic, large cell, desmoplastic/nodular, and medulloblastoma with extensive nodularity. Recent work with gene expression profiling along with histological classification has generated a novel combined histopathological and molecular stratification scheme into 4 subgroups (Wnt, Shh, group 3, and group 4). This could now help to identify patients who might benefit from dose escalation and de-escalation of therapy. Restratification brings optimism in treating these patients as scholars now have the ability to profile a more targeted therapy approach. This review discusses the literature regarding this new research endeavor.
- Published
- 2012
- Full Text
- View/download PDF
36. Adult-onset cerebral folate deficiency.
- Author
-
Sadighi Z, Butler IJ, and Koenig MK
- Subjects
- Brain Diseases diet therapy, Female, Humans, Leucovorin administration & dosage, Middle Aged, Vitamin B Deficiency diet therapy, Brain Diseases complications, Brain Diseases pathology, Cerebral Cortex pathology, Vitamin B Deficiency complications
- Abstract
Objective: To report new manifestations of cerebral folate deficiency, a rare metabolic autoimmune syndrome,in an adult., Design: Case report., Setting: University teaching hospital., Patient: A 58-year-old woman with progressive memory loss and myoclonus presented for medical attention. Results of cerebral spinal fluid analysis showed low levels of tetrahydrobiopterin and 5-methyltetrahydrofolate. The patient's serum folate level was normal. Serum contained folate receptor 1 blocking and binding antibodies., Results: The patient was treated successfully with folinic acid supplementation, and after 6 months of treatment,clinical symptoms had resolved., Conclusions: To our knowledge, we report the first case of adult-onset cerebral folate deficiency. Furthermore, this condition could represent a treatable form of early-onset dementia.
- Published
- 2012
- Full Text
- View/download PDF
37. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
- Author
-
Sadighi S, Mohagheghi MA, Montazeri A, and Sadighi Z
- Subjects
- Adenocarcinoma physiopathology, Adenocarcinoma psychology, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cisplatin administration & dosage, Disease-Free Survival, Docetaxel, Epirubicin administration & dosage, Female, Fluorouracil administration & dosage, Humans, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Quality of Life, Stomach Neoplasms physiopathology, Stomach Neoplasms psychology, Survival Rate, Taxoids administration & dosage, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy
- Abstract
Background: Health related quality of life (HRQOL) is an important outcome after treatment for upper gastrointestinal carcinoma. This study aimed to compare HRQOL in patients with advanced gastric cancer (GC) receiving either a standard or an experimental treatment., Methods: Seventy-one patients have been treated in Cancer Institute (Tehran, Iran) with docetaxel, cisplatin, 5 FU (TCF) or epirubicin, cisplatin, 5-FU (ECF) and were followed from Jan 2002 to Jan 2005. End points were response rate, HRQOL and survival. HRQOL was assessed using the EORCT QLQ-C30 at baseline and after the third cycle of chemotherapy., Results: The baseline HRQOL scores were comparable between two groups. After treatment improvement was seen in a number of items and domains except for cognitive functioning, and diarrhoea. Pain decreased and physical functioning improved in both groups. However, only the TCF group showed statistically and clinically meaningful improvement in global QOL (P = 0.001). Surgical and pathologic response was better with TCF but there was no difference in survival rate between two groups., Conclusion: Docetaxel based treatment (TCF) showed better palliation and improvement of global QOL as compared with epirubicin based treatment (ECF). However, it seems that regardless of treatment offered, effective chemotherapy was the most important factor affecting QOL in these patients.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.